-transparent.png){kind=logo}
Four human T cell lines, TL-Mor, TL-Su, TL-TerI, and TL-OmI, carrying human T cell leukemia virus (HTLV), were established previously. TL-Mor, TL-Su, and TL-TerI were derived from interleukin 2 (IL-2)-dependent parental cell lines cloned from peripheral blood leukocytes (PBL) of three healthy HTLV carriers, while TL-OmI was directly established from PBL of a patient with adult T cell leukemia. These four TL cell lines grow autonomously without IL-2. When they were cultured in the presence of IL-2, their growth was inhibited after a few days. This growth inhibition depended on the dose of IL-2, and the effective dose significantly promoted growth of their parental IL-2-dependent cell lines. The growth inhibition is demonstrated to be due to specific binding of IL-2 to receptors on the TL cells.
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
March 1994,
International journal of oncology,
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
November 1993,
Blood,
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
December 1994,
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
August 1981,
Blut,
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
February 1993,
Immunology letters,
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
January 1984,
Princess Takamatsu symposia,
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
May 1995,
Cytokine,
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
January 1983,
International journal of immunopharmacology,
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
January 1981,
Immunology today,
K Sugamura, and
S Nakai, and
M Fujii, and
Y Hinuma
December 1980,
Immunology today,
